Dupilumab Compassionate Use Study
- Sponsor
- Sally E. Wenzel MD
- Study ID
- NCT03020810
- Status
- Approved For Marketing
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dupilumab — DRUGThe patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
Study Details
This is a single patient expanded access, compassionate and non-emergency use study that provides patients with severe asthma, who do not qualify for ongoing clinical trials with dupilumab, access to this investigational treatment.
Key Dates
- Status verified
- Mar 2018
Related Studies
- Role of Genetic Factors in the Development of Lung DiseaseRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Personalized Environment and Genes StudyRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent AsthmaRecruiting · Gelb, Arthur F., M.D. · Lakewood, California
- Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway InflammationPHASE1 · Recruiting · Benjamin Medoff · Boston, Massachusetts